Cancer Research Cell Death Mechanisms and Cancer Therapy Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christensen, J. G.
Right arrow Articles by Mendel, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christensen, J. G.
Right arrow Articles by Mendel, D. B.
[Cancer Research 63, 7345-7355, November 1, 2003]
© 2003 American Association for Cancer Research

Regular Articles

A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

James G. Christensen1, Randall Schreck, Jon Burrows, Poonam Kuruganti, Emily Chan, Phuong Le, Jeffrey Chen, Xueyan Wang, Lany Ruslim, Robert Blake, Kenneth E. Lipson, John Ramphal, Steven Do, Jingrong J. Cui, Julie M. Cherrington and Dirk B. Mendel

Preclinical Research and Exploratory Development [J. G. C., R. S., J. B., P. K., E. C., J. M. C., D. B. M.], Discovery Technology and Biology [P. L., J. C., X. W., L. R., R. B., K. E. L.], and Chemistry [J. R., S. D., J. J. C.], SUGEN, Inc., South San Francisco, California 94080

The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the development and progression of several human cancers and are attractive targets for cancer therapy. PHA-665752 was identified as a small molecule, ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (Ki 4 nM). PHA-665752 also exhibited >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. In cellular studies, PHA-665752 potently inhibited HGF-stimulated and constitutive c-Met phosphorylation, as well as HGF and c-Met-driven phenotypes such as cell growth (proliferation and survival), cell motility, invasion, and/or morphology of a variety of tumor cells. In addition, PHA-665752 inhibited HGF-stimulated or constitutive phosphorylation of mediators of downstream signal transduction of c-Met, including Gab-1, extracellular regulated kinase, Akt, signal transducer and activator of transcription 3, phospholipase C {gamma}, and focal adhesion kinase, in multiple tumor cell lines in a pattern correlating to the phenotypic response of a given tumor cell. In in vivo studies, a single dose of PHA-665752 inhibited c-Met phosphorylation in tumor xenografts for up to 12 h. Inhibition of c-Met phosphorylation was associated with dose-dependent tumor growth inhibition/growth delay over a repeated administration schedule at well-tolerated doses. Interestingly, potent cytoreductive activity was demonstrated in a gastric carcinoma xenograft model. Collectively, these results demonstrate the feasibility of selectively targeting c-Met with ATP-competitive small-molecules and suggest the therapeutic potential of targeting c-Met in human cancers.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, et al.
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Clin. Cancer Res., November 1, 2009; 15(21): 6630 - 6638.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Lal, C. R. Goodwin, Y. Sang, C. A. Foss, K. Cornet, S. Muzamil, M. G. Pomper, J. Kim, and J. Laterra
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts
Mol. Cancer Ther., July 1, 2009; 8(7): 1751 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. Knowles, L. P. Stabile, A. M. Egloff, M. E. Rothstein, S. M. Thomas, C. T. Gubish, E. C. Lerner, R. R. Seethala, S. Suzuki, K. M. Quesnelle, et al.
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Clin. Cancer Res., June 1, 2009; 15(11): 3740 - 3750.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Coxon, K. Rex, S. Meyer, J. Sun, J. Sun, Q. Chen, R. Radinsky, R. Kendall, and T. L. Burgess
Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models
Mol. Cancer Ther., May 1, 2009; 8(5): 1119 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Bonuccelli, M. C. Casimiro, F. Sotgia, C. Wang, M. Liu, S. Katiyar, J. Zhou, E. Dew, F. Capozza, K. M. Daumer, et al.
Caveolin-1 (P132L), a Common Breast Cancer Mutation, Confers Mammary Cell Invasiveness and Defines a Novel Stem Cell/Metastasis-Associated Gene Signature
Am. J. Pathol., May 1, 2009; 174(5): 1650 - 1662.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
N. Smotrov, A. Mathur, I. Kariv, C. M. Moxham, and N. Bays
Development of a Cell-Based Assay for Measurement of c-Met Phosphorylation Using AlphaScreenTM Technology and High-Content Imaging Analysis
J Biomol Screen, April 1, 2009; 14(4): 404 - 411.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Li, F. Guessous, C. DiPierro, Y. Zhang, T. Mudrick, L. Fuller, E. Johnson, L. Marcinkiewicz, M. Engelhardt, B. Kefas, et al.
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Mol. Cancer Ther., February 1, 2009; 8(2): 376 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. N. Kongkham, P. A. Northcott, Y. S. Ra, Y. Nakahara, T. G. Mainprize, S. E. Croul, C. A. Smith, M. D. Taylor, and J. T. Rutka
An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma
Cancer Res., December 1, 2008; 68(23): 9945 - 9953.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
P. Giacobini, A. Messina, F. Morello, N. Ferraris, S. Corso, J. Penachioni, S. Giordano, L. Tamagnone, and A. Fasolo
Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex
J. Cell Biol., November 3, 2008; 183(3): 555 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Bachleitner-Hofmann, M. Y. Sun, C.-T. Chen, L. Tang, L. Song, Z. Zeng, M. Shah, J. G. Christensen, N. Rosen, D. B. Solit, et al.
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
Mol. Cancer Ther., November 1, 2008; 7(11): 3499 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
A. Korostylev, T. Worzfeld, S. Deng, R. H. Friedel, J. M. Swiercz, P. Vodrazka, V. Maier, A. Hirschberg, Y. Ohoka, S. Inagaki, et al.
A functional role for semaphorin 4D/plexin B1 interactions in epithelial branching morphogenesis during organogenesis
Development, October 15, 2008; 135(20): 3333 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults
Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth
Cancer Res., October 1, 2008; 68(19): 7838 - 7845.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
G. K.Y. Chan, B. A. Lutterbach, B.-S. Pan, I. Kariv, and A. A. Szewczak
High-Throughput Analysis of HGF-Stimulated Cell Scattering
J Biomol Screen, October 1, 2008; 13(9): 847 - 854.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Toschi and P. A. Janne
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli
A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al.
A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway
Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. R. Sierra, S. Corso, L. Caione, V. Cepero, P. Conrotto, A. Cignetti, W. Piacibello, A. Kumanogoh, H. Kikutani, P. M. Comoglio, et al.
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
J. Exp. Med., July 7, 2008; 205(7): 1673 - 1685.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
B. Peruzzi and D. P Bottaro
Targeting the c-Met Signaling Pathway in Cancer
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 61 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Yang, M. Wislez, N. Fujimoto, L. Prudkin, J. G. Izzo, F. Uno, L. Ji, A. E. Hanna, R. R. Langley, D. Liu, et al.
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
Mol. Cancer Ther., April 1, 2008; 7(4): 952 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al.
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors
Clin. Cancer Res., April 1, 2008; 14(7): 2220 - 2226.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
Z. Yablonka-Reuveni, K. Day, A. Vine, and G. Shefer
Defining the transcriptional signature of skeletal muscle stem cells
J Anim Sci, April 1, 2008; 86(14_suppl): E207 - E216.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al.
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra
Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor
Mol. Cancer Res., January 1, 2008; 6(1): 139 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, and G. Los
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Mol. Cancer Ther., December 1, 2007; 6(12): 3314 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi
Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. D. Tolbert, J. Daugherty, C. Gao, Q. Xie, C. Miranti, E. Gherardi, G. Vande Woude, and H. E. Xu
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist
PNAS, September 11, 2007; 104(37): 14592 - 14597.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile
Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer
Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, and F. M. White
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
PNAS, July 31, 2007; 104(31): 12867 - 12872.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Arena, A. Pisacane, M. Mazzone, P. M. Comoglio, and A. Bardelli
Genetic targeting of the kinase activity of the Met receptor in cancer cells
PNAS, July 3, 2007; 104(27): 11412 - 11417.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, et al.
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science, May 18, 2007; 316(5827): 1039 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P.-P. Kung, et al.
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
Cancer Res., May 1, 2007; 67(9): 4408 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia
A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts
Cancer Res., April 15, 2007; 67(8): 3529 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Corsino, B. Davis, M. Law, A. Chytil, E. Forrester, P. Norgaard, N. Teoh, and B. Law
Tumors Initiated by Constitutive Cdk2 Activation Exhibit Transforming Growth Factor {beta} Resistance and Acquire Paracrine Mitogenic Stimulation during Progression
Cancer Res., April 1, 2007; 67(7): 3135 - 3144.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. D. Francone, R. G. Landmann, C.-T. Chen, M. Y. Sun, E. J. Kuntz, Z. Zeng, R. P. Dematteo, P. B. Paty, and M. R. Weiser
Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors
Mol. Cancer Ther., April 1, 2007; 6(4): 1460 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
Blood, April 1, 2007; 109(7): 3024 - 3030.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Z. Yu, P. M. Weinberger, C. Sasaki, B. L. Egleston, W. F. Speier IV, B. Haffty, D. Kowalski, R. Camp, D. Rimm, E. Vairaktaris, et al.
Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 553 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Tsuda, I. J. Davis, P. Argani, N. Shukla, G. G. McGill, M. Nagai, T. Saito, M. Lae, D. E. Fisher, and M. Ladanyi
TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition
Cancer Res., February 1, 2007; 67(3): 919 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al.
Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Iliopoulos
Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy
Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS
J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al.
Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.
Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. Mazzone and P. M. Comoglio
The Met pathway: master switch and drug target in cancer progression
FASEB J, August 1, 2006; 20(10): 1611 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. P. Stabile, J. S. Lyker, S. R. Land, S. Dacic, B. A. Zamboni, and J. M. Siegfried
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer
Carcinogenesis, August 1, 2006; 27(8): 1547 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Peruzzi and D. P. Bottaro
Targeting the c-Met Signaling Pathway in Cancer.
Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Petrelli, P. Circosta, L. Granziero, M. Mazzone, A. Pisacane, S. Fenoglio, P. M. Comoglio, and S. Giordano
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
PNAS, March 28, 2006; 103(13): 5090 - 5095.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. S. Melnick, J. Janes, S. Kim, J. Y. Chang, D. G. Sipes, D. Gunderson, L. Jarnes, J. T. Matzen, M. E. Garcia, T. L. Hood, et al.
An efficient rapid system for profiling the cellular activities of molecular libraries
PNAS, February 28, 2006; 103(9): 3153 - 3158.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, W. J. Kim, R. A. Okimoto, D. W. Bell, D. C. Sgroi, et al.
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
PNAS, February 14, 2006; 103(7): 2316 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Sangwan, G. N. Paliouras, A. Cheng, N. Dube, M. L. Tremblay, and M. Park
Protein-tyrosine Phosphatase 1B Deficiency Protects against Fas-induced Hepatic Failure
J. Biol. Chem., January 6, 2006; 281(1): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al.
Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung
J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne
Inhibition of the Met Receptor in Mesothelioma
Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. Abounader and J. Laterra
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Neuro-oncol, October 1, 2005; 7(4): 436 - 451.
[Abstract] [PDF]

Home page
 ChestHome page
T.-L. Cheng, M.-Y. Chang, S.-Y. Huang, C.-C. Sheu, E.-L. Kao, Y.-J. Cheng, and I.-W. Chong
Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer
Chest, September 1, 2005; 128(3): 1453 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. R. D'Andrea, J. M. Mei, R. W. Tuman, R. A. Galemmo, and D. L. Johnson
Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis
Mol. Cancer Ther., August 1, 2005; 4(8): 1198 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Lal, S. Xia, R. Abounader, and J. Laterra
Targeting the c-Met Pathway Potentiates Glioblastoma Responses to {gamma}-Radiation
Clin. Cancer Res., June 15, 2005; 11(12): 4479 - 4486.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al.
Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma
Cancer Res., June 1, 2005; 65(11): 4598 - 4606.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. C. Ma, E. Schaefer, J. G. Christensen, and R. Salgia
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Clin. Cancer Res., March 15, 2005; 11(6): 2312 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Shinomiya, C. F. Gao, Q. Xie, M. Gustafson, D. J. Waters, Y.-W. Zhang, and G. F. Vande Woude
RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival
Cancer Res., November 1, 2004; 64(21): 7962 - 7970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.